Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.92
NAS:ALIM's Cash-to-Debt is ranked lower than
64% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NAS:ALIM: 0.92 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALIM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 2.59 Max: 508.46
Current: 0.92
0.32
508.46
Equity-to-Asset 0.36
NAS:ALIM's Equity-to-Asset is ranked lower than
82% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NAS:ALIM: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALIM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.37 Max: 0.46
Current: 0.36
-0.25
0.46
Piotroski F-Score: 4
Altman Z-Score: -6.35
Beneish M-Score: -2.64
WACC vs ROIC
21.24%
-97.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -81.11
NAS:ALIM's Operating Margin % is ranked lower than
87% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. NAS:ALIM: -81.11 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALIM' s Operating Margin % Range Over the Past 10 Years
Min: -1837.82  Med: -282.49 Max: -81.11
Current: -81.11
-1837.82
-81.11
Net Margin % -96.62
NAS:ALIM's Net Margin % is ranked lower than
87% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NAS:ALIM: -96.62 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALIM' s Net Margin % Range Over the Past 10 Years
Min: -2469.5  Med: -281.46 Max: -96.62
Current: -96.62
-2469.5
-96.62
ROE % -149.93
NAS:ALIM's ROE % is ranked lower than
94% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NAS:ALIM: -149.93 )
Ranked among companies with meaningful ROE % only.
NAS:ALIM' s ROE % Range Over the Past 10 Years
Min: -299.13  Med: -104.32 Max: -61.59
Current: -149.93
-299.13
-61.59
ROA % -49.30
NAS:ALIM's ROA % is ranked lower than
88% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NAS:ALIM: -49.30 )
Ranked among companies with meaningful ROA % only.
NAS:ALIM' s ROA % Range Over the Past 10 Years
Min: -329.68  Med: -48.29 Max: -20.46
Current: -49.3
-329.68
-20.46
ROC (Joel Greenblatt) % -298.44
NAS:ALIM's ROC (Joel Greenblatt) % is ranked lower than
87% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. NAS:ALIM: -298.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALIM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12190.35  Med: -3400.49 Max: -298.44
Current: -298.44
-12190.35
-298.44
3-Year Revenue Growth Rate 122.50
NAS:ALIM's 3-Year Revenue Growth Rate is ranked higher than
99% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NAS:ALIM: 122.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALIM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 122.5
Current: 122.5
0
122.5
3-Year EBITDA Growth Rate -24.10
NAS:ALIM's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. NAS:ALIM: -24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ALIM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.6 Max: 5.6
Current: -24.1
0
5.6
3-Year EPS without NRI Growth Rate -27.00
NAS:ALIM's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NAS:ALIM: -27.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ALIM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.35 Max: 19.6
Current: -27
0
19.6
GuruFocus has detected 1 Warning Sign with Alimera Sciences Inc $NAS:ALIM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALIM's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALIM Guru Trades in Q3 2015

Jim Simons 127,149 sh (New)
» More
Q4 2015

ALIM Guru Trades in Q4 2015

Jim Simons 75,200 sh (-40.86%)
» More
Q1 2016

ALIM Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q4 2016

ALIM Guru Trades in Q4 2016

Jim Simons 59,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:BIOYF, AMEX:NNVC, NAS:OASM, NAS:PRPH, AMEX:AXN, NAS:NVGN, NAS:IMNP, NAS:ALQA, OTCPK:SUWN, NAS:TNXP, OTCPK:INNV, AMEX:CPHI, NAS:BSPM, OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB, NAS:ZGNX, NAS:NBRV, NAS:RMTI, NAS:ASMB » details
Traded in other countries:ASZ.Germany,
Alimera Sciences Inc is a pharmaceutical company. The Company, along with its subsidiaries is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Alimera Sciences is a biopharmaceutical company engaged in the research, development, and commercialization of ophthalmic pharmaceuticals. The company presently focuses on diseases affecting the back of the eye, or retina, and looks to improve upon current therapies with its pipeline drug candidates.

Ratios

vs
industry
vs
history
PS Ratio 2.06
ALIM's PS Ratio is ranked higher than
62% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. ALIM: 2.06 )
Ranked among companies with meaningful PS Ratio only.
ALIM' s PS Ratio Range Over the Past 10 Years
Min: 1.55  Med: 18.95 Max: 853.33
Current: 2.06
1.55
853.33
Current Ratio 5.20
ALIM's Current Ratio is ranked higher than
79% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. ALIM: 5.20 )
Ranked among companies with meaningful Current Ratio only.
ALIM' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.2 Max: 8.76
Current: 5.2
0.59
8.76
Quick Ratio 5.15
ALIM's Quick Ratio is ranked higher than
81% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. ALIM: 5.15 )
Ranked among companies with meaningful Quick Ratio only.
ALIM' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.15 Max: 8.76
Current: 5.15
0.59
8.76
Days Inventory 170.67
ALIM's Days Inventory is ranked lower than
75% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. ALIM: 170.67 )
Ranked among companies with meaningful Days Inventory only.
ALIM' s Days Inventory Range Over the Past 10 Years
Min: 155.56  Med: 292.87 Max: 445.49
Current: 170.67
155.56
445.49
Days Sales Outstanding 147.12
ALIM's Days Sales Outstanding is ranked lower than
84% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. ALIM: 147.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALIM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.83  Med: 122.31 Max: 159.4
Current: 147.12
36.83
159.4
Days Payable 776.40
ALIM's Days Payable is ranked higher than
99% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. ALIM: 776.40 )
Ranked among companies with meaningful Days Payable only.
ALIM' s Days Payable Range Over the Past 10 Years
Min: 339.92  Med: 802.71 Max: 1270.92
Current: 776.4
339.92
1270.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.10
ALIM's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. ALIM: -27.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -175  Med: -6.25 Max: 0
Current: -27.1
-175
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.11
ALIM's Price-to-Median-PS-Value is ranked higher than
98% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. ALIM: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALIM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.82 Max: 4.12
Current: 0.11
0.08
4.12
Earnings Yield (Greenblatt) % -16.90
ALIM's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. ALIM: -16.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALIM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -833.3  Med: 0 Max: 0
Current: -16.9
-833.3
0

More Statistics

Revenue (TTM) (Mil) $34.33
EPS (TTM) $ -0.63
Beta2.74
Short Percentage of Float2.23%
52-Week Range $1.02 - 5.15
Shares Outstanding (Mil)64.86
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

More From Other Websites
ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017 Mar 27 2017
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8% Mar 14 2017
Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain Mar 13 2017
ALIMERA SCIENCES INC Financials Mar 09 2017
Alimera Sciences to Present at the 29th Annual ROTH Conference Mar 07 2017
ALIMERA SCIENCES INC Files SEC form 10-K, Annual Report Mar 03 2017
Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference Mar 03 2017
Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT Mar 02 2017
Alimera Sciences reports 4Q loss Mar 02 2017
Alimera Sciences reports 4Q loss Mar 02 2017
ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2017
Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Q4 2016 Alimera Sciences Inc Earnings Release - After Market Close Mar 01 2017
Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017 Feb 23 2017
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in... Feb 22 2017
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in... Feb 22 2017
Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy Feb 06 2017
ETFs with exposure to Alimera Sciences, Inc. : January 11, 2017 Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)